Drug target
•Download as PPTX, PDF•
0 likes•721 views
This document discusses Alzheimer's disease and potential drug targets and strategies. It begins by introducing Alzheimer's disease and some of its key characteristics like memory loss and neuronal cell dysfunction. It then discusses amyloid beta and its role in Alzheimer's disease pathology. Several current and potential drug targets are mentioned, like acetylcholinesterase inhibitors and NMDA receptors. The document also discusses using biomarkers from sources like platelets and CSF to aid diagnosis and validate drug targets. Methodologies like proteomics and various assays are mentioned for identifying these biomarkers. Overall the goal is to identify novel targets and strategies to enhance cognition and slow disease progression.
Report
Share
Report
Share
Recommended
Scb alzforum
1) The document presents research analyzing blood biomarkers to predict neocortical amyloid beta (Aβ) burden, which is associated with Alzheimer's disease.
2) The research uses data from cohorts within the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) to develop and validate statistical models combining blood-based biomarkers with clinical data to predict Aβ burden.
3) The most accurate model achieved a sensitivity of 79.6%, specificity of 82.4%, and AUC of 87.6% for predicting Aβ burden, demonstrating the potential of blood-based biomarkers for early detection of Alzheimer's disease.
Alzforum Berislav Zlokovic
Leaky Blood-Brain Barrier a Harbinger of Alzheimer s Disease - presentation made at Alzforum's live webinar of February 17, 2015. See details at: http://www.alzforum.org/webinars/leaky-blood-brain-barrier-harbinger-alzheimers
M&m may09f
The document discusses giant cell arteritis (GCA), a medical condition that can cause vision loss. It provides details on:
1) How GCA causes vision loss by occluding the posterior ciliary arteries and cutting off blood flow to the optic nerve head.
2) Laboratory results and angiography findings of a patient with bilateral vision loss due to GCA.
3) Factors that may allow some vision recovery in a small percentage of patients, such as restoration of blood pressure at night or effects of corticosteroid treatment.
4) Guidelines for diagnosis, treatment with steroids, and monitoring of GCA patients to prevent further vision loss.
Dr Matthew Campbell - AGM 2011 - AMD Drug Delivery
Dr Matthew Campbell (TCD) explains the latest developments out of the Trinity lab in the development of new drug therapies to treat Age-related Macular Degeneration.
Opthalmology
This patient presented with transient monocular vision loss and was found to have an irregular heartbeat, flushed face, and purpuric skin lesions. Investigations revealed atrial fibrillation and a mid-diastolic heart murmur. The most likely diagnosis is infective endocarditis given the clinical findings and heart abnormalities on examination.
The Appearance of Alzheimer's in the Brain
Dr. Dominic D'Agostino studies Alzheimer's disease and related neurological conditions. The brain tissue of an Alzheimer's patient features two abnormalities: beta-amyloid plaques, which disrupt cellular communication, and tau protein tangles, which destroy the brain's transport system and cause cellular death. A new theory suggests that metabolic dysregulation leads to the abnormal folding of beta-amyloid and tau proteins, indicating Alzheimer's pathology results from impaired brain energy metabolism. An ongoing study is investigating the use of ketogenic diets or ketone supplements to enhance brain metabolism as a potential Alzheimer's treatment strategy.
Crown Regulatory Affairs post-graduate certificate 2016 - Eylea new indications
Crown Regulatory Affairs post-graduate certificate 2016 - Eylea new indicationsPharmaceutical Compliance Inspection unit, Crown College of Canada
Crown Medical Research and Pharmaceutical Sciences College of Canada.
Achieve your career goals in a short period of time with a very competitive education and get Canadian experience with the highest quality of supervised training.
Crown Medical Research and Pharmaceutical Sciences College of Canada offers opportunities to expand your experience beyond the classroom and support them with guidance on career opportunities.
Our professors, consultants, and course developers are recognized leaders in professional development and training in the field of pharmaceutical, natural health products, quality assurance and quality control, regulatory affairs and submissions, pharmacovigilance and drug safety reporting, clinical research, cosmetics, food sciences, biopharmaceutical, and health care policy and services management.
We strive to continuously evolve and expand our programs in an attempt to respond effectively to changing technologies and workforce demands in the industry. It is with this strategy that our programs will prepare our learners for their future.
When attending our college, you will be exposed to highly qualified professionals and professors as well as students with diverse backgrounds and proven professional abilities seeking to improve their skill set and employment outlook.
We are located at Richmond Hill, in the Greater Toronto Area, that is one of the 3 biggest financial and social center in North America. This gives learners access to the head quarters of many industries and to be exposed to personal, and professional growth opportunities.
Our college offers academic counseling program through one-on-one meetings with professors and collaborators and we offer faculty-mentoring program to assist students in improving their learning and working strategies for reaching faster their career goals.
When you are considering to enroll in a certificate course offered by our college, please explore the program information on the website and contact us for a one-on-one mentoring meeting, to visit the campus, and to get a career consultation at any time. Our intensive courses start every month and our learners can start their program with us at any time during the year.
Visual Outcome After Cataract Surgery In Patients With Retinitis Pigmentosa.
This document summarizes a study on visual outcomes after cataract surgery in patients with retinitis pigmentosa (RP). The study reviewed 52 eyes of RP patients who underwent cataract surgery. It found that preoperative vision was poor, with 94% having vision worse than 6/60. After surgery, vision improved to ≥6/18 in 45.2% of patients. However, vision did not improve in 53.8% of patients. Better postoperative vision was associated with less advanced RP. The type of cataract, age of patient, or surgery type did not significantly affect outcomes. Final vision was better for phacoemulsification with IOL than for manual small-incision cataract
Recommended
Scb alzforum
1) The document presents research analyzing blood biomarkers to predict neocortical amyloid beta (Aβ) burden, which is associated with Alzheimer's disease.
2) The research uses data from cohorts within the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) to develop and validate statistical models combining blood-based biomarkers with clinical data to predict Aβ burden.
3) The most accurate model achieved a sensitivity of 79.6%, specificity of 82.4%, and AUC of 87.6% for predicting Aβ burden, demonstrating the potential of blood-based biomarkers for early detection of Alzheimer's disease.
Alzforum Berislav Zlokovic
Leaky Blood-Brain Barrier a Harbinger of Alzheimer s Disease - presentation made at Alzforum's live webinar of February 17, 2015. See details at: http://www.alzforum.org/webinars/leaky-blood-brain-barrier-harbinger-alzheimers
M&m may09f
The document discusses giant cell arteritis (GCA), a medical condition that can cause vision loss. It provides details on:
1) How GCA causes vision loss by occluding the posterior ciliary arteries and cutting off blood flow to the optic nerve head.
2) Laboratory results and angiography findings of a patient with bilateral vision loss due to GCA.
3) Factors that may allow some vision recovery in a small percentage of patients, such as restoration of blood pressure at night or effects of corticosteroid treatment.
4) Guidelines for diagnosis, treatment with steroids, and monitoring of GCA patients to prevent further vision loss.
Dr Matthew Campbell - AGM 2011 - AMD Drug Delivery
Dr Matthew Campbell (TCD) explains the latest developments out of the Trinity lab in the development of new drug therapies to treat Age-related Macular Degeneration.
Opthalmology
This patient presented with transient monocular vision loss and was found to have an irregular heartbeat, flushed face, and purpuric skin lesions. Investigations revealed atrial fibrillation and a mid-diastolic heart murmur. The most likely diagnosis is infective endocarditis given the clinical findings and heart abnormalities on examination.
The Appearance of Alzheimer's in the Brain
Dr. Dominic D'Agostino studies Alzheimer's disease and related neurological conditions. The brain tissue of an Alzheimer's patient features two abnormalities: beta-amyloid plaques, which disrupt cellular communication, and tau protein tangles, which destroy the brain's transport system and cause cellular death. A new theory suggests that metabolic dysregulation leads to the abnormal folding of beta-amyloid and tau proteins, indicating Alzheimer's pathology results from impaired brain energy metabolism. An ongoing study is investigating the use of ketogenic diets or ketone supplements to enhance brain metabolism as a potential Alzheimer's treatment strategy.
Crown Regulatory Affairs post-graduate certificate 2016 - Eylea new indications
Crown Regulatory Affairs post-graduate certificate 2016 - Eylea new indicationsPharmaceutical Compliance Inspection unit, Crown College of Canada
Crown Medical Research and Pharmaceutical Sciences College of Canada.
Achieve your career goals in a short period of time with a very competitive education and get Canadian experience with the highest quality of supervised training.
Crown Medical Research and Pharmaceutical Sciences College of Canada offers opportunities to expand your experience beyond the classroom and support them with guidance on career opportunities.
Our professors, consultants, and course developers are recognized leaders in professional development and training in the field of pharmaceutical, natural health products, quality assurance and quality control, regulatory affairs and submissions, pharmacovigilance and drug safety reporting, clinical research, cosmetics, food sciences, biopharmaceutical, and health care policy and services management.
We strive to continuously evolve and expand our programs in an attempt to respond effectively to changing technologies and workforce demands in the industry. It is with this strategy that our programs will prepare our learners for their future.
When attending our college, you will be exposed to highly qualified professionals and professors as well as students with diverse backgrounds and proven professional abilities seeking to improve their skill set and employment outlook.
We are located at Richmond Hill, in the Greater Toronto Area, that is one of the 3 biggest financial and social center in North America. This gives learners access to the head quarters of many industries and to be exposed to personal, and professional growth opportunities.
Our college offers academic counseling program through one-on-one meetings with professors and collaborators and we offer faculty-mentoring program to assist students in improving their learning and working strategies for reaching faster their career goals.
When you are considering to enroll in a certificate course offered by our college, please explore the program information on the website and contact us for a one-on-one mentoring meeting, to visit the campus, and to get a career consultation at any time. Our intensive courses start every month and our learners can start their program with us at any time during the year.
Visual Outcome After Cataract Surgery In Patients With Retinitis Pigmentosa.
This document summarizes a study on visual outcomes after cataract surgery in patients with retinitis pigmentosa (RP). The study reviewed 52 eyes of RP patients who underwent cataract surgery. It found that preoperative vision was poor, with 94% having vision worse than 6/60. After surgery, vision improved to ≥6/18 in 45.2% of patients. However, vision did not improve in 53.8% of patients. Better postoperative vision was associated with less advanced RP. The type of cataract, age of patient, or surgery type did not significantly affect outcomes. Final vision was better for phacoemulsification with IOL than for manual small-incision cataract
Drug Target Identification
Hepatitis B is a liver infection caused by the HBV virus. It can lead to liver failure or cancer. The core protein and viral DNA polymerase (P protein) are potential drug targets. Lamivudine and telbivudine are approved drugs that target the P protein. Derivatives of these drugs were created and their properties analyzed. Docking showed that a lamivudine derivative followed Lipinski's rules best and could be a future potential treatment for hepatitis B.
Target identification in drug discovery
The document discusses target identification in drug discovery. It begins by defining a target and explaining that target identification is the first step in drug discovery. It then discusses various approaches to target identification, including direct biochemical methods, genetic interaction methods, and computational inference methods. The document also discusses characteristics of drug targets and how drugs interact with targets at the molecular level. It provides examples of tools that can be used for target identification and validation, such as microarrays, antisense technology, and proteomics. In summary, the document outlines the process of target identification in drug discovery and various methods that can be used to identify and validate potential drug targets.
Sources of drugs
Drugs are obtained from six major sources: plant sources, animal sources, mineral/earth sources, microbiological sources, semi-synthetic sources, and recombinant DNA technology. Plant sources provide many older drugs and include poppy flowers, tobacco leaves, and ipecacuanha roots. Animal sources such as sheep thyroid and cod liver are used. Mineral sources include metals like iron and non-metals like iodine. Microbiological sources provide antibiotics from fungi and bacteria. Semi-synthetic drugs are modified from natural sources, while synthetic drugs have altered chemical structures. Recombinant DNA technology produces drugs by inserting genes into bacterial cultures.
Nomenclature and classification of drugs
This document discusses the nomenclature and classification of drugs. It explains that drugs have three different names: a chemical name, non-proprietary name, and proprietary name. The chemical name provides the precise molecular structure, while the non-proprietary name is concise and not subject to proprietary rights. Proprietary names are given by pharmaceutical companies. Drugs can be classified in several ways including by their chemical nature, source, target organ or site of action, mode of action, therapeutic use, or physiological system. The classification method used depends on the perspective and background of the person discussing the drugs.
Drug Classifications
This document categorizes and describes various cardiac drugs used to treat heart conditions. It lists drug classes including ACE inhibitors, calcium channel blockers, beta blockers, diuretics, vasopressors, and antidysrhythmics. For each drug class, it provides a brief description of the drug's actions, such as its effects on contractility, heart rate, and blood pressure. Side effects are also noted for some classes. The document serves as a reference for nurses on the classifications, uses, and adverse effects of common cardiac medications.
Introduction to Drug Target Identification
1. The document discusses the history of antibiotic discovery and the growing problem of antimicrobial resistance driving the need for new drugs. It highlights key discoveries like penicillin but notes resistance grew quickly.
2. It then covers the molecular mechanisms that enable intrinsic and acquired drug resistance in bacteria. Intrinsic resistance includes inherent cellular defenses while acquired resistance develops through genetic mutations or transfer.
3. The rise of multidrug-resistant bacterial pathogens is a major concern as it reduces the effectiveness of current antibiotic treatments. New drug targets and antibiotics are urgently needed to address drug-resistant infections.
Classification of drugs
Drugs can be classified pharmacologically based on their chemical makeup and characteristics or therapeutically based on their intended effects. Allopathic drugs work by producing effects opposite to the disease symptoms and can be prescription or over-the-counter. Non-prescription drugs are available without a prescription and are used to treat conditions like acne, coughs, hemorrhoids, and more. They include analgesics, antacids, antihistamines, antiseptics, and other drug classes.
Drug classifications
This document discusses drug classifications and provides examples of therapeutic and pharmacologic classifications. Therapeutic classifications group drugs based on their intended effects, while pharmacologic classifications group drugs based on their mechanisms of action. The document gives angiotensin-converting enzyme (ACE) inhibitors as an example of a pharmacologic class, noting they all end in "pril" and work by blocking the conversion of angiotensin I to angiotensin II. It describes the indications, therapeutic effects, side effects, and nursing considerations for ACE inhibitors.
Alzheimer's Disease Final Presentation
This document summarizes the mission and timeline of the Neuro Group project to discover new secretase inhibitor drug leads for neurodegeneration and Alzheimer's disease. The group aims to address the unmet medical need in Alzheimer's by discovering and developing safe and effective drug leads. Their plan involves studying the disease pathway and factors involved in neurodegeneration, screening drug candidates for secretase inhibition and blood-brain barrier permeability, and developing intellectual property around promising lead compounds.
Antibody Aducanumab Reduces Αβ Plaques in Alzheimer’s Disease
Journal Club presentation prepared for Stony Brook University, Department of Psychiatry. Explains findings of "The Antibody Aducanumab Reduces Αβ Plaques in Alzheimer’s Disease," Sevigny et al, Nature, Vol 537, 1 September 2016.
Neuroimmunology update
The document discusses recent advances in neuroimmunology, specifically regarding autoimmunity in the central nervous system. It covers how the CNS was once considered an immunologically privileged site but is now known to mount intrathecal immune responses. Several autoimmune disorders of the CNS are described, including multiple sclerosis, neuromyelitis optica spectrum disorders, and autoimmune encephalitides associated with antibodies against neuronal surface antigens. Laboratory testing for various neuronal antibodies is also summarized.
Test File
This document discusses advances in understanding and treating dementia and neurodegenerative diseases. It notes that dementia affects over 18 million people worldwide and costs over $5.5 billion annually in Canada. Challenges include early detection, understanding disease pathogenesis through autopsy, animal and in vitro models. Biomarkers like neuroimaging and biochemical markers in serum and CSF may enable early detection. Current FDA-approved treatments for Alzheimer's include cholinesterase inhibitors but future therapies aim to reduce amyloid and tau accumulation or prevent neuronal loss through various targets. Animal models expressing human proteins help study pathogenesis and protein aggregation's role across neurodegenerative diseases.
Integrativeproject
This document discusses diagnosing Alzheimer's disease ante mortem (before death). It notes that current diagnosis relies on biomarkers like amyloid plaques and tau proteins seen during autopsy, but these are not accurate until death. The document argues that objective neuropsychological testing can help diagnose Alzheimer's earlier by measuring declines in memory, executive function, visuospatial skills, and verbal abilities. It reviews biomarkers like the apolipoprotein E ε4 allele that are risk factors but not definitive diagnoses. The goal is to establish a neurocognitive profile to improve accuracy of diagnosing Alzheimer's disease before severe symptoms develop.
Genetica clinica diaria_sin_videos
This document discusses genetic testing and next generation sequencing. It provides an overview of different types of genetic testing including diagnostic, predictive, carrier, prenatal, newborn screening, pharmacogenomic, and research testing. Benefits and drawbacks of genetic testing are outlined. The document then focuses on whole exome sequencing, describing what parts of the genome it examines, its characteristics, and limitations. Details are given about the next generation sequencing process and various applications. Case examples are presented to demonstrate clinical use and findings from whole exome sequencing.
Biomarker Diagnosis for Alzheimer's Disease
This document discusses biomarkers for the diagnosis of Alzheimer's disease. It defines biomarkers and describes their use to detect, stage, and monitor Alzheimer's. Biomarkers found in cerebrospinal fluid include decreased Aβ42 and increased total tau and phosphorylated tau. Genetic markers like mutations in APP, PSEN1 and PSEN2 can cause early-onset Alzheimer's. Circulating miRNAs show potential as non-invasive blood biomarkers. Mass spectrometry is used to analyze various protein biomarkers but none have been satisfactory for diagnosis. Reliable blood biomarkers are still being sought to allow early, fast and non-invasive Alzheimer's diagnosis.
Alzheimer's disease
This document summarizes the molecular basis of Alzheimer's disease. It begins by describing Alzheimer's as a progressive neurodegenerative disorder characterized by memory loss and cognitive decline. Key pathological features are amyloid plaques and neurofibrillary tangles in the brain. The accumulation of these proteins is thought to lead to synaptic loss, neuronal death, and the cognitive symptoms of the disease. Current drug therapies can only temporarily improve symptoms but do not stop the underlying disease progression. Researchers are actively investigating strategies to modify the disease course by targeting amyloid production, clearance, or aggregation in the brain. While promising approaches are being studied, there are currently no approved disease-modifying treatments for Alzheimer's.
Neuroscience research services
Creative Biolabs' dedicated team of neuroscience CRO scientists want the same thing as you do: to find a cure for the devastating diseases of the central nervous system. Learn more, please visit https://neuros.creative-biolabs.com/antibody-discovery-services.htm.
Alzheimer disease
This Slide describes progression of alzheimer disease and the changes that occurs in alzheimer disease. Also it describes how the disease progress to different parts of brain and which different part of brain are involved in it. It is made by Gopal Agarwal, Ph.D Research Scholar, NIPER-Ahmedabad
Therapeutic Targeting of Alzheimer's Disease with a Selective Antibody
Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization.
Overview of Alzheimer's disease
Alzheimer's disease is a neurodegenerative disorder with severe dementia. Due to the accumulation of Beta-Amyloid proteins acetyl-choline producing neurons are getting degenerated. Alzheimer's disease is one of the most devastating brain disorders of elderly humans. It is an under-treated and under-recognized disease that is becoming a major public health problem.
Alzheimer's disease
Pharmacotherapy of Alzheimer's disease
Introduction
History
Risk factors
Pathophysiology
Symptoms
Diagnosis
Non pharmacological treatment
Drugs used in treatment of Alzheimer`s
Recent advances
Screening methods
Summary
References
Prime valerio zerbi
This document describes a study investigating the effects of multi-nutrient enriched diets on a mouse model of Alzheimer's disease. The study aims to examine how diets supplemented with DHA, EPA, UMP, choline, phospholipids, and vitamins impact the pathophysiology of AD. Mice are fed either a control diet, DHA+EPA enriched diet, or a multi-nutrient fortified diet. Outcome measures include 1H magnetic resonance spectroscopy to analyze neuronal and glial markers, and cerebral blood flow measurements using FAIR imaging. The goal is to determine if nutrient enriched diets can restore cerebral perfusion and protect against neurodegeneration in an APP/PS1 mouse model of Alzheimer's disease.
More Related Content
Viewers also liked
Drug Target Identification
Hepatitis B is a liver infection caused by the HBV virus. It can lead to liver failure or cancer. The core protein and viral DNA polymerase (P protein) are potential drug targets. Lamivudine and telbivudine are approved drugs that target the P protein. Derivatives of these drugs were created and their properties analyzed. Docking showed that a lamivudine derivative followed Lipinski's rules best and could be a future potential treatment for hepatitis B.
Target identification in drug discovery
The document discusses target identification in drug discovery. It begins by defining a target and explaining that target identification is the first step in drug discovery. It then discusses various approaches to target identification, including direct biochemical methods, genetic interaction methods, and computational inference methods. The document also discusses characteristics of drug targets and how drugs interact with targets at the molecular level. It provides examples of tools that can be used for target identification and validation, such as microarrays, antisense technology, and proteomics. In summary, the document outlines the process of target identification in drug discovery and various methods that can be used to identify and validate potential drug targets.
Sources of drugs
Drugs are obtained from six major sources: plant sources, animal sources, mineral/earth sources, microbiological sources, semi-synthetic sources, and recombinant DNA technology. Plant sources provide many older drugs and include poppy flowers, tobacco leaves, and ipecacuanha roots. Animal sources such as sheep thyroid and cod liver are used. Mineral sources include metals like iron and non-metals like iodine. Microbiological sources provide antibiotics from fungi and bacteria. Semi-synthetic drugs are modified from natural sources, while synthetic drugs have altered chemical structures. Recombinant DNA technology produces drugs by inserting genes into bacterial cultures.
Nomenclature and classification of drugs
This document discusses the nomenclature and classification of drugs. It explains that drugs have three different names: a chemical name, non-proprietary name, and proprietary name. The chemical name provides the precise molecular structure, while the non-proprietary name is concise and not subject to proprietary rights. Proprietary names are given by pharmaceutical companies. Drugs can be classified in several ways including by their chemical nature, source, target organ or site of action, mode of action, therapeutic use, or physiological system. The classification method used depends on the perspective and background of the person discussing the drugs.
Drug Classifications
This document categorizes and describes various cardiac drugs used to treat heart conditions. It lists drug classes including ACE inhibitors, calcium channel blockers, beta blockers, diuretics, vasopressors, and antidysrhythmics. For each drug class, it provides a brief description of the drug's actions, such as its effects on contractility, heart rate, and blood pressure. Side effects are also noted for some classes. The document serves as a reference for nurses on the classifications, uses, and adverse effects of common cardiac medications.
Introduction to Drug Target Identification
1. The document discusses the history of antibiotic discovery and the growing problem of antimicrobial resistance driving the need for new drugs. It highlights key discoveries like penicillin but notes resistance grew quickly.
2. It then covers the molecular mechanisms that enable intrinsic and acquired drug resistance in bacteria. Intrinsic resistance includes inherent cellular defenses while acquired resistance develops through genetic mutations or transfer.
3. The rise of multidrug-resistant bacterial pathogens is a major concern as it reduces the effectiveness of current antibiotic treatments. New drug targets and antibiotics are urgently needed to address drug-resistant infections.
Classification of drugs
Drugs can be classified pharmacologically based on their chemical makeup and characteristics or therapeutically based on their intended effects. Allopathic drugs work by producing effects opposite to the disease symptoms and can be prescription or over-the-counter. Non-prescription drugs are available without a prescription and are used to treat conditions like acne, coughs, hemorrhoids, and more. They include analgesics, antacids, antihistamines, antiseptics, and other drug classes.
Drug classifications
This document discusses drug classifications and provides examples of therapeutic and pharmacologic classifications. Therapeutic classifications group drugs based on their intended effects, while pharmacologic classifications group drugs based on their mechanisms of action. The document gives angiotensin-converting enzyme (ACE) inhibitors as an example of a pharmacologic class, noting they all end in "pril" and work by blocking the conversion of angiotensin I to angiotensin II. It describes the indications, therapeutic effects, side effects, and nursing considerations for ACE inhibitors.
Viewers also liked (8)
Similar to Drug target
Alzheimer's Disease Final Presentation
This document summarizes the mission and timeline of the Neuro Group project to discover new secretase inhibitor drug leads for neurodegeneration and Alzheimer's disease. The group aims to address the unmet medical need in Alzheimer's by discovering and developing safe and effective drug leads. Their plan involves studying the disease pathway and factors involved in neurodegeneration, screening drug candidates for secretase inhibition and blood-brain barrier permeability, and developing intellectual property around promising lead compounds.
Antibody Aducanumab Reduces Αβ Plaques in Alzheimer’s Disease
Journal Club presentation prepared for Stony Brook University, Department of Psychiatry. Explains findings of "The Antibody Aducanumab Reduces Αβ Plaques in Alzheimer’s Disease," Sevigny et al, Nature, Vol 537, 1 September 2016.
Neuroimmunology update
The document discusses recent advances in neuroimmunology, specifically regarding autoimmunity in the central nervous system. It covers how the CNS was once considered an immunologically privileged site but is now known to mount intrathecal immune responses. Several autoimmune disorders of the CNS are described, including multiple sclerosis, neuromyelitis optica spectrum disorders, and autoimmune encephalitides associated with antibodies against neuronal surface antigens. Laboratory testing for various neuronal antibodies is also summarized.
Test File
This document discusses advances in understanding and treating dementia and neurodegenerative diseases. It notes that dementia affects over 18 million people worldwide and costs over $5.5 billion annually in Canada. Challenges include early detection, understanding disease pathogenesis through autopsy, animal and in vitro models. Biomarkers like neuroimaging and biochemical markers in serum and CSF may enable early detection. Current FDA-approved treatments for Alzheimer's include cholinesterase inhibitors but future therapies aim to reduce amyloid and tau accumulation or prevent neuronal loss through various targets. Animal models expressing human proteins help study pathogenesis and protein aggregation's role across neurodegenerative diseases.
Integrativeproject
This document discusses diagnosing Alzheimer's disease ante mortem (before death). It notes that current diagnosis relies on biomarkers like amyloid plaques and tau proteins seen during autopsy, but these are not accurate until death. The document argues that objective neuropsychological testing can help diagnose Alzheimer's earlier by measuring declines in memory, executive function, visuospatial skills, and verbal abilities. It reviews biomarkers like the apolipoprotein E ε4 allele that are risk factors but not definitive diagnoses. The goal is to establish a neurocognitive profile to improve accuracy of diagnosing Alzheimer's disease before severe symptoms develop.
Genetica clinica diaria_sin_videos
This document discusses genetic testing and next generation sequencing. It provides an overview of different types of genetic testing including diagnostic, predictive, carrier, prenatal, newborn screening, pharmacogenomic, and research testing. Benefits and drawbacks of genetic testing are outlined. The document then focuses on whole exome sequencing, describing what parts of the genome it examines, its characteristics, and limitations. Details are given about the next generation sequencing process and various applications. Case examples are presented to demonstrate clinical use and findings from whole exome sequencing.
Biomarker Diagnosis for Alzheimer's Disease
This document discusses biomarkers for the diagnosis of Alzheimer's disease. It defines biomarkers and describes their use to detect, stage, and monitor Alzheimer's. Biomarkers found in cerebrospinal fluid include decreased Aβ42 and increased total tau and phosphorylated tau. Genetic markers like mutations in APP, PSEN1 and PSEN2 can cause early-onset Alzheimer's. Circulating miRNAs show potential as non-invasive blood biomarkers. Mass spectrometry is used to analyze various protein biomarkers but none have been satisfactory for diagnosis. Reliable blood biomarkers are still being sought to allow early, fast and non-invasive Alzheimer's diagnosis.
Alzheimer's disease
This document summarizes the molecular basis of Alzheimer's disease. It begins by describing Alzheimer's as a progressive neurodegenerative disorder characterized by memory loss and cognitive decline. Key pathological features are amyloid plaques and neurofibrillary tangles in the brain. The accumulation of these proteins is thought to lead to synaptic loss, neuronal death, and the cognitive symptoms of the disease. Current drug therapies can only temporarily improve symptoms but do not stop the underlying disease progression. Researchers are actively investigating strategies to modify the disease course by targeting amyloid production, clearance, or aggregation in the brain. While promising approaches are being studied, there are currently no approved disease-modifying treatments for Alzheimer's.
Neuroscience research services
Creative Biolabs' dedicated team of neuroscience CRO scientists want the same thing as you do: to find a cure for the devastating diseases of the central nervous system. Learn more, please visit https://neuros.creative-biolabs.com/antibody-discovery-services.htm.
Alzheimer disease
This Slide describes progression of alzheimer disease and the changes that occurs in alzheimer disease. Also it describes how the disease progress to different parts of brain and which different part of brain are involved in it. It is made by Gopal Agarwal, Ph.D Research Scholar, NIPER-Ahmedabad
Therapeutic Targeting of Alzheimer's Disease with a Selective Antibody
Whiteboard2Boardroom presents innovations from regional universities, hospitals, research organizations to encourage commercialization.
Overview of Alzheimer's disease
Alzheimer's disease is a neurodegenerative disorder with severe dementia. Due to the accumulation of Beta-Amyloid proteins acetyl-choline producing neurons are getting degenerated. Alzheimer's disease is one of the most devastating brain disorders of elderly humans. It is an under-treated and under-recognized disease that is becoming a major public health problem.
Alzheimer's disease
Pharmacotherapy of Alzheimer's disease
Introduction
History
Risk factors
Pathophysiology
Symptoms
Diagnosis
Non pharmacological treatment
Drugs used in treatment of Alzheimer`s
Recent advances
Screening methods
Summary
References
Prime valerio zerbi
This document describes a study investigating the effects of multi-nutrient enriched diets on a mouse model of Alzheimer's disease. The study aims to examine how diets supplemented with DHA, EPA, UMP, choline, phospholipids, and vitamins impact the pathophysiology of AD. Mice are fed either a control diet, DHA+EPA enriched diet, or a multi-nutrient fortified diet. Outcome measures include 1H magnetic resonance spectroscopy to analyze neuronal and glial markers, and cerebral blood flow measurements using FAIR imaging. The goal is to determine if nutrient enriched diets can restore cerebral perfusion and protect against neurodegeneration in an APP/PS1 mouse model of Alzheimer's disease.
Drug development in Alzheimer's Disease
Presentation outlining new techniques and issues with regard to drug development in Alzheimer's patients, by Dr. Samer Kaba of Medpace.
BME 626_Alzheimers_ Nanomedical Systems
This document summarizes a proposed nanoparticle system to remove amyloid-β aggregates in vitro for the treatment of Alzheimer's disease. The system uses multifunctional iron-oxide nanoparticles coated with dextran and biotinylated anti-amyloid-β antibodies. The nanoparticles are designed to cross the blood-brain barrier via activation of adenosine receptors on brain endothelial cells, then target and remove amyloid-β aggregates using an applied magnetic field. The document outlines the synthesis, characterization, and testing of the nanoparticles, including in vitro studies on cell lines and brain tissue, as well as potential issues to address such as blood-brain barrier permeability, dose optimization, and toxicity evaluation.
Alzheimer's presentation by urooj umer
Alzheimer's disease is a progressive brain disorder that causes memory loss and cognitive decline. The main pathological features are amyloid plaques and neurofibrillary tangles in the brain. Risk factors include age and family history. Symptoms include memory loss, problems with thinking and language, and behavioral changes. A diagnosis is made based on medical history, cognitive tests, and brain imaging. Currently, treatment focuses on managing symptoms with medications and lifestyle changes. Research continues on developing disease-modifying therapies to slow or stop progression.
Etiology of TAU & PLAQUE protein in Alzheimer's Disease
Details of Alzheimer's Disease and Etiology of Protein.
Under the guidance of
Mr. Nilanjan Adhikari
Assistant professor,Department of Pharmacology
P.G INSTITUTE OF MEDICAL SCIENCES
Alzheimer's disease
This document discusses Alzheimer's disease including its causes, symptoms, diagnosis and treatment. It is a neurodegenerative disease that causes memory loss and cognitive decline. The main pathologies involved are beta-amyloid plaques and neurofibrillary tangles composed of tau proteins. Diagnosis involves assessing cognitive impairment and ruling out other conditions, while treatments can help symptoms but currently there is no cure as brain cells continue to be lost.
Hanipsych, bdnf in alzh.
Higher levels of the protein brain-derived neurotrophic factor (BDNF) may protect against Alzheimer's disease and dementia. BDNF targets cortical brain cells, preventing their death and improving learning and memory. Studies have also found that higher serum BDNF levels can protect against future occurrence of dementia and Alzheimer's. Future research may examine using BDNF levels to predict Alzheimer's risk or giving BDNF supplements to older adults to prevent or reduce symptoms.
Similar to Drug target (20)
Antibody Aducanumab Reduces Αβ Plaques in Alzheimer’s Disease
Antibody Aducanumab Reduces Αβ Plaques in Alzheimer’s Disease
Therapeutic Targeting of Alzheimer's Disease with a Selective Antibody
Therapeutic Targeting of Alzheimer's Disease with a Selective Antibody
Etiology of TAU & PLAQUE protein in Alzheimer's Disease
Etiology of TAU & PLAQUE protein in Alzheimer's Disease
More from Ravi Anand
data-acquisition-system-ppt
Data acquisition involves sampling signals from physical processes, converting the analog signals to digital numeric values, and processing the data with a computer. Data acquisition systems typically use transducers to sense physical variables and convert them to electrical signals, condition the signals for analog to digital conversion, and convert the signals to digital formats for computer processing, analysis, storage and display. Signal conditioning improves signal quality and may include amplification, isolation, filtering and linearization. Analog to digital converters change analog voltage or current levels into digital values that computers can process.
Methods for Voltage Stability Enhancement
This document discusses various methods for enhancing voltage stability in power systems, including using lower power factor generators, capacitor banks, controlling transformer tap changers, undervoltage load shedding, coordination of protections and controls, control of network voltage and generator reactive output, use of FACTS devices, artificial neural networks, fuzzy logic, excitation control, booster transformers, phase shifting transformers, secondary voltage regulation, series capacitors, and must-run generation. It provides details on how each method can be implemented and their effectiveness.
Automation And Robotics
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise causes chemical changes in the brain that may help alleviate symptoms of mental illness and boost overall mental well-being.
Automation And Robotics
The document discusses the results of a study on the effects of a new drug on memory and cognitive function in older adults. The double-blind study involved giving either the new drug or a placebo to 100 volunteers aged 65-80 over a 6 month period. Testing showed those receiving the drug experienced statistically significant improvements in short-term memory retention and processing speed compared to the placebo group.
ANALOG TO DIGITAL COMMUNICATION {MODULATION}
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
Seminar Report on MHD (Magneto Hydro Dynamics)
This document provides a technical seminar report on magneto hydrodynamic (MHD) power generation. It discusses the working principle of MHD generators, provides a brief history of MHD, describes the different types of MHD generators (Faraday, Hall, and disc generators), and discusses how MHD generators can be integrated with conventional thermal power plants to improve efficiency. The document concludes that MHD power generation offers efficiency improvements over conventional systems and has the potential to help address growing energy demands.
8086
The 8086 microprocessor is a 16-bit CPU launched by Intel in 1978. It has a 16-bit data bus and 20-bit address bus, allowing it to access up to 1MB of memory. The 8086 architecture partitions the CPU logic into two functional units - the Bus Interface Unit which handles external transactions, and the Execution Unit which performs decoding and execution. This separation improves processing speed by allowing parallel instruction fetching and execution via pipelining. The 8086 uses memory segmentation to access more memory than its 16-bit registers allow, dividing the 1MB address space into 64KB segments addressed using segment and offset registers.
Electrical Design of Transmission Line
Notes of Microprocessor provided by Prof.Anjali Gupta mam NIET,Greater Noida
Electrical Design of Transmission Line
Notes of Microprocessor provided by Prof.Anjali Gupta mam NIET,Greater Noida
Electrical Design of Transmission Line
Notes of Microprocessor provided by Prof.Anjali Gupta mam NIET,Greater Noida
Introduction to 8085 Microprocessor
The document discusses microprocessors, microcontrollers, and the 8085 microprocessor. It defines a microprocessor as a programmable device that performs arithmetic and logical operations on numbers according to a stored program. A microcontroller is similar but has memory and I/O functions integrated on a single chip. The 8085 is an 8-bit microprocessor with 40 pins that can address 64KB of memory and has 74 instructions across 5 addressing modes. It uses multiplexed address and data lines to reduce pins.
8085 instruction set (detailed)
The document describes the instruction set of the 8085 microprocessor. It is divided into 5 categories: data transfer instructions, arithmetic instructions, logical instructions, branching instructions, and control instructions. The data transfer instructions include MOV, MVI, LDA, STA, etc. to move data between registers and memory. The arithmetic instructions perform operations like addition, subtraction, increment, decrement. The logical instructions include AND, OR, XOR logical operations.
Microprocessor 8086 instructions
The document describes the instruction set of the 8086 microprocessor. It discusses 6 types of instructions supported: 1) data transfer instructions, 2) arithmetic instructions, 3) logical instructions, 4) string manipulation instructions, 5) process control instructions, and 6) control transfer instructions. Details are provided on the various instructions under each type, including their mnemonics and functions.
8086
The 8086 microprocessor is a 16-bit CPU launched by Intel in 1978. It has a 16-bit data bus and 20-bit address bus, allowing it to access up to 1MB of memory. The 8086 architecture partitions the CPU logic into two functional units - the Bus Interface Unit which handles external transactions, and the Execution Unit which performs decoding and execution. This separation improves processing speed by allowing parallel instruction fetching and execution via pipelining. The 8086 uses memory segmentation to access more memory than its 16-bit registers allow, dividing the 1MB address space into 64KB segments addressed using segment and offset registers.
8086 instructions
The 8086 instruction set is the native instruction set of the Intel 8086 CPU. It includes basic arithmetic and logic instructions like ADD, SUB, AND, OR, as well as data transfer instructions like MOV, PUSH, POP. The instruction set also features conditional jump and loop instructions like JMP, JZ, JNZ, LOOP for control flow.
8086 instructions
The 8086 instruction set includes 8 categories of instructions: data transfer, arithmetic, branch, loop, machine control, flag manipulation, shift/rotate, and string instructions. Some key instructions include MOV for data transfer, PUSH/POP for stack operations, ADD/SUB for arithmetic, JMP for branching, LOOP for looping, and SHIFT/ROTATE for bitwise operations.
Microprocessor 8086 notes
The 8086 processor has a 1MB address space divided into two 512KB banks connected to the lower and upper halves of the 16-bit data bus. Data can be accessed from memory in 8-bit or 16-bit sizes from either the even or odd address banks using different combinations of address lines and enabling the appropriate bank. Accessing 16-bit data starting from an odd address requires two bus cycles to retrieve the lower byte first from the odd bank then the upper byte from the even bank by incrementing the address.
Emmi (imp. question)
This document contains an assignment with questions about electrical measurement instruments. It asks the student to describe the construction and working principles of thermocouple instruments, electrostatic and rectifier type instruments, single phase and three phase wattmeters, and single phase energy meters. It also asks the student to discuss errors and remedies in single phase wattmeters and energy meters, and derive the torque equations of single phase wattmeters and energy meters.
Cro (emmi) (3)
The document discusses the cathode ray oscilloscope (CRO) and how it can be used as a voltmeter and ammeter by connecting it across components or measuring voltage drops across resistors. It explains how to read measurements from a CRO, such as measuring time period by multiplying the distance between cycles by the time base setting. Finally, it notes that the CRO can be used to study AC waveforms, with mains electricity in Europe operating at 50 Hz and the relationship between peak and RMS voltages.
More from Ravi Anand (20)
Recently uploaded
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS Template 2023-2024 by: Irene S. Rueco
Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...
Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...National Information Standards Organization (NISO)
This presentation was provided by Steph Pollock of The American Psychological Association’s Journals Program, and Damita Snow, of The American Society of Civil Engineers (ASCE), for the initial session of NISO's 2024 Training Series "DEIA in the Scholarly Landscape." Session One: 'Setting Expectations: a DEIA Primer,' was held June 6, 2024.Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Dr. Vinod Kumar Kanvaria
Exploiting Artificial Intelligence for Empowering Researchers and Faculty,
International FDP on Fundamentals of Research in Social Sciences
at Integral University, Lucknow, 06.06.2024
By Dr. Vinod Kumar KanvariaISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
Denis is a dynamic and results-driven Chief Information Officer (CIO) with a distinguished career spanning information systems analysis and technical project management. With a proven track record of spearheading the design and delivery of cutting-edge Information Management solutions, he has consistently elevated business operations, streamlined reporting functions, and maximized process efficiency.
Certified as an ISO/IEC 27001: Information Security Management Systems (ISMS) Lead Implementer, Data Protection Officer, and Cyber Risks Analyst, Denis brings a heightened focus on data security, privacy, and cyber resilience to every endeavor.
His expertise extends across a diverse spectrum of reporting, database, and web development applications, underpinned by an exceptional grasp of data storage and virtualization technologies. His proficiency in application testing, database administration, and data cleansing ensures seamless execution of complex projects.
What sets Denis apart is his comprehensive understanding of Business and Systems Analysis technologies, honed through involvement in all phases of the Software Development Lifecycle (SDLC). From meticulous requirements gathering to precise analysis, innovative design, rigorous development, thorough testing, and successful implementation, he has consistently delivered exceptional results.
Throughout his career, he has taken on multifaceted roles, from leading technical project management teams to owning solutions that drive operational excellence. His conscientious and proactive approach is unwavering, whether he is working independently or collaboratively within a team. His ability to connect with colleagues on a personal level underscores his commitment to fostering a harmonious and productive workplace environment.
Date: May 29, 2024
Tags: Information Security, ISO/IEC 27001, ISO/IEC 42001, Artificial Intelligence, GDPR
-------------------------------------------------------------------------------
Find out more about ISO training and certification services
Training: ISO/IEC 27001 Information Security Management System - EN | PECB
ISO/IEC 42001 Artificial Intelligence Management System - EN | PECB
General Data Protection Regulation (GDPR) - Training Courses - EN | PECB
Webinars: https://pecb.com/webinars
Article: https://pecb.com/article
-------------------------------------------------------------------------------
For more information about PECB:
Website: https://pecb.com/
LinkedIn: https://www.linkedin.com/company/pecb/
Facebook: https://www.facebook.com/PECBInternational/
Slideshare: http://www.slideshare.net/PECBCERTIFICATION
The Diamonds of 2023-2024 in the IGRA collection
A review of the growth of the Israel Genealogy Research Association Database Collection for the last 12 months. Our collection is now passed the 3 million mark and still growing. See which archives have contributed the most. See the different types of records we have, and which years have had records added. You can also see what we have for the future.
How to Add Chatter in the odoo 17 ERP Module
In Odoo, the chatter is like a chat tool that helps you work together on records. You can leave notes and track things, making it easier to talk with your team and partners. Inside chatter, all communication history, activity, and changes will be displayed.
ANATOMY AND BIOMECHANICS OF HIP JOINT.pdf
it describes the bony anatomy including the femoral head , acetabulum, labrum . also discusses the capsule , ligaments . muscle that act on the hip joint and the range of motion are outlined. factors affecting hip joint stability and weight transmission through the joint are summarized.
How to Make a Field Mandatory in Odoo 17
In Odoo, making a field required can be done through both Python code and XML views. When you set the required attribute to True in Python code, it makes the field required across all views where it's used. Conversely, when you set the required attribute in XML views, it makes the field required only in the context of that particular view.
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
This Dissertation explores the particular circumstances of Mirzapur, a region located in the
core of India. Mirzapur, with its varied terrains and abundant biodiversity, offers an optimal
environment for investigating the changes in vegetation cover dynamics. Our study utilizes
advanced technologies such as GIS (Geographic Information Systems) and Remote sensing to
analyze the transformations that have taken place over the course of a decade.
The complex relationship between human activities and the environment has been the focus
of extensive research and worry. As the global community grapples with swift urbanization,
population expansion, and economic progress, the effects on natural ecosystems are becoming
more evident. A crucial element of this impact is the alteration of vegetation cover, which plays a
significant role in maintaining the ecological equilibrium of our planet.Land serves as the foundation for all human activities and provides the necessary materials for
these activities. As the most crucial natural resource, its utilization by humans results in different
'Land uses,' which are determined by both human activities and the physical characteristics of the
land.
The utilization of land is impacted by human needs and environmental factors. In countries
like India, rapid population growth and the emphasis on extensive resource exploitation can lead
to significant land degradation, adversely affecting the region's land cover.
Therefore, human intervention has significantly influenced land use patterns over many
centuries, evolving its structure over time and space. In the present era, these changes have
accelerated due to factors such as agriculture and urbanization. Information regarding land use and
cover is essential for various planning and management tasks related to the Earth's surface,
providing crucial environmental data for scientific, resource management, policy purposes, and
diverse human activities.
Accurate understanding of land use and cover is imperative for the development planning
of any area. Consequently, a wide range of professionals, including earth system scientists, land
and water managers, and urban planners, are interested in obtaining data on land use and cover
changes, conversion trends, and other related patterns. The spatial dimensions of land use and
cover support policymakers and scientists in making well-informed decisions, as alterations in
these patterns indicate shifts in economic and social conditions. Monitoring such changes with the
help of Advanced technologies like Remote Sensing and Geographic Information Systems is
crucial for coordinated efforts across different administrative levels. Advanced technologies like
Remote Sensing and Geographic Information Systems
9
Changes in vegetation cover refer to variations in the distribution, composition, and overall
structure of plant communities across different temporal and spatial scales. These changes can
occur natural.
BÀI TẬP BỔ TRỢ TIẾNG ANH 8 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2023-2024 (CÓ FI...
BÀI TẬP BỔ TRỢ TIẾNG ANH 8 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2023-2024 (CÓ FI...Nguyen Thanh Tu Collection
https://app.box.com/s/y977uz6bpd3af4qsebv7r9b7s21935vdAdvanced Java[Extra Concepts, Not Difficult].docx
This is part 2 of my Java Learning Journey. This contains Hashing, ArrayList, LinkedList, Date and Time Classes, Calendar Class and more.
Main Java[All of the Base Concepts}.docx
This is part 1 of my Java Learning Journey. This Contains Custom methods, classes, constructors, packages, multithreading , try- catch block, finally block and more.
Hindi varnamala | hindi alphabet PPT.pdf
हिंदी वर्णमाला पीपीटी, hindi alphabet PPT presentation, hindi varnamala PPT, Hindi Varnamala pdf, हिंदी स्वर, हिंदी व्यंजन, sikhiye hindi varnmala, dr. mulla adam ali, hindi language and literature, hindi alphabet with drawing, hindi alphabet pdf, hindi varnamala for childrens, hindi language, hindi varnamala practice for kids, https://www.drmullaadamali.com
The simplified electron and muon model, Oscillating Spacetime: The Foundation...
Discover the Simplified Electron and Muon Model: A New Wave-Based Approach to Understanding Particles delves into a groundbreaking theory that presents electrons and muons as rotating soliton waves within oscillating spacetime. Geared towards students, researchers, and science buffs, this book breaks down complex ideas into simple explanations. It covers topics such as electron waves, temporal dynamics, and the implications of this model on particle physics. With clear illustrations and easy-to-follow explanations, readers will gain a new outlook on the universe's fundamental nature.
Recently uploaded (20)
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...
Pollock and Snow "DEIA in the Scholarly Landscape, Session One: Setting Expec...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
Film vocab for eal 3 students: Australia the movie
Film vocab for eal 3 students: Australia the movie
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
BÀI TẬP BỔ TRỢ TIẾNG ANH 8 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2023-2024 (CÓ FI...
BÀI TẬP BỔ TRỢ TIẾNG ANH 8 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2023-2024 (CÓ FI...
Digital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental Design
Liberal Approach to the Study of Indian Politics.pdf
Liberal Approach to the Study of Indian Politics.pdf
The simplified electron and muon model, Oscillating Spacetime: The Foundation...
The simplified electron and muon model, Oscillating Spacetime: The Foundation...
Drug target
- 1. DRUG TARGETS AND DRUG DESIGN Ms. Sanchi Dua M. Tech. Biotechnology (2009-11)
- 2. Introduction: Alzheimer's Disease • Progressive Neurodegenerative Disorder • Acute Cognitive Decline Neuronal Cell Dysfunction Memory Loss Poorly understood
- 3. Amyloid Beta (Aβ) Aβ (betaamyloid peptide) Hallmark of Alzheimer's disease (AD) Yeast Cells used to study harmful effects
- 4. Pathological Characterization • Accumulation of extracellular beta amyloid (Aβ) plaques • Intracellular tau tangles • Gliosis • Neuronal cell death
- 5. Research Objective Identify biomarkers • Peripheral Biomarkers • Blood samples easy to obtain Novel cognitive- • Increased Efficacy and Safety enhancing therapeutic strategies
- 6. Existing clinical methods of diagnosis Brain Imaging Characterizing fluid biomarkers Cerebrospinal fluid (CSF)
- 7. Blood-based biomarkers Potential sources Platelets Small, anuclear fragments derived from megakaryocytes in the bone marrow Platelets Respond to neurotransmitters Enzymes responsible for generating the Aβ peptide. High concentration of amyloid precursor protein (APP)
- 8. Methodology for identifying Biomarkers Validation of Cooccurrence of other pooled analyte changes consistent with previous biomarker studies Platelet isolation and membrane protein enrichment Quantification of membrane-enriched proteome
- 10. Current drug targets To improve cognitive function Inhibit acetylcholinesterase (AChE) N-methyl-D-aspartate receptor
- 11. Novel cognitive-enhancing therapeutic strategies To slow disease progression in AD patients To enhance cognitive function
- 12. Potential Drug Targets Metabotropic glutamate receptor subtype 5 • Increasing the activation of mGlu5 Nicotinic acetylcholine receptor • Activation of the α7nAChR subtype with smallmolecule agonists M1 Muscarinic acetylcholine receptors • potential to affect multiple disease pathologies including amyloid-beta and phosphorylated tau
- 13. Potential Drug Targets • Indirect cholinergic 5Hydroxytryptamine stimulation through 5-hydroxytryptamine receptors (5-HT) receptors 6 Norepinephrine • Noradrenergic neurons: vulnerable during aging Cyclic adenosine monophosphate • cAMP signaling is increased with aging
- 14. Experimental Techniques • Immunostaining • Immunoblot • Indirect ELISA Assay • Mass spectrometry (MS)-based proteomics